2012 Toxicology Division Symposia and Activities
SUNDAY MORNING
Role of pharmacogenetics in oncology
San Diego Convention Center, Room 5A
9:30 am – 12:00 pm
Sponsored by the Divisions for Toxicology; Drug Metabolism; and Integrative Systems, Translational & Clinical Pharmacology
Chairs: E. Penni Black, Univ. of Kentucky and Hollie Swanson, Univ. of Kentucky Col. of Med.
Impact of CY2D6 polymorphisms on patient response to tamoxifen.
Matthew Goetz, Mayo Clinic
Utilizing gene expression signatures to predict response to targeted therapies in lung and colorectal cancer.
E. Penni Black, Univ. of Kentucky
A personalized medicine case study in NSCLC: Crizotinib story.
Hakan Sakul, Pfizer
Activation of AMP-dependent kinase and treatment of lung cancers.
Richard Moran, Virginia Comm. Univ.
SUNDAY AFTERNOON
Role of nuclear receptors in lipid dysregulation and obesity-related diseases
San Diego Convention Center, Room 5A
3:00 pm – 5:30 pm
Sponsored by the Divisions for Drug Metabolism; Integrative Systems, Translational & Clinical Pharmacology; and Toxicology
Chairs: John Chiang, Northeastern Ohio Univ. Col. of Med. And Hollie Swanson, Univ. of Kentucky Col. of Med.
Introduction.
Hollie Swanson, Univ. of Kentucky Col. of Med.
PXR and CAR as therapeutic targets for obesity type 2 diabetes.
Wen Xie, Univ. of Pittsburgh Sch. of Pharm.
Bile acid activated receptors in regulating lipid and glucose metabolism.
Stefano Fiorucci, Univ. of Perugia, Italy
Tissue specific functions of the farnesoid X receptor in liver and intestine.
Grace Guo, Univ. of Kansas Med. Center
Impact of selective estrogen receptor beta ligands on obesity.
Ramesh Narayanan, GTx, Inc.
Graduate Student/Postdoc Poster Competition
Marriott Hotel, Marriott Hall 3/4
6:30 pm - 8:30 pm
MONDAY MORNING
Cognitive enhancement to improve treatment outcome and quality of life associated with neuropathologies
San Diego Convention Center, Room 3
9:30 am – 12:00 pm
Sponsored by the Divisions for Behavioral Pharmacology; Neuropharmacology; and Toxicology
Chairs: Robert Gould, Wake Forest Univ. Sch. of Med. and Michael A. Nader, Wake Forest Univ. Sch. of Med.
Models of cognition and their predictive validity.
Robert Gould, Wake Forest Univ. Sch. of Med.
Cognitive deficits associated with cancer chemotherapy and potential pharmacological treatments.
Ellen Walker, Temple Univ. Sch. of Pharm.
Neurobiological, functional, and cognitive deficits associated with cocaine addiction.
Sam Deadwyler, Wake Forest Univ. Hlth. Sci.
Cognitive deficits associated with Parkinson's disease: Clinical and pre-clinical perspectives.
Jay Schneider, Thomas Jefferson Univ., Jeff. Med. Col.
Nicotinic acetylcholine receptors as targets for cognitive enhancement.
Martin Sarter, Univ. of Michigan
TUESDAY MORNING
From structure to knockout: Common themes between CYPs and ABC transporters
San Diego Convention Center, Room 5A
9:30 am – 12:00 pm
Sponsored by the Divisions for Toxicology; Drug Metabolism; and Drug Discovery, Development & Regulatory Affairs; and Neuropharmacology
Chair: Mary Vore, Univ. of Kentucky
Structure of multidrug resistance transporters.
Geoffrey Chang, Univ. of California, San Diego
Structural characteristics of drug metabolizing P450s: Implications for drug development.
Eric F. Johnson, Scripps Res. Inst.
Role of ABC transporters in ADME-- Translation from knockout mice to clinics.
Yuichi Sugiyama, Univ. of Tokyo Sch. of Pharmaceut. Sci.
Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment.
Frank Gonzalez, NCI, NIH
TUESDAY AFTERNOON
Toxicology Division Symposium: The utilization of genetically modified mice to determine mechanisms of toxicity
San Diego Convention Center, Room 5A
3:00 pm – 5:30 pm
Chairs: Jack A. Hinson, Univ. of Arkansas for Med. Sci.
Introduction.
Jack A. Hinson, Univ. of Arkansas for Med. Sci.
Role of P450 and nuclear receptor transgenic mice in determining mechanisms of chemical hepatotoxicity.
Frank J. Gonzalez, NCI, NIH
Transgenic mouse models for modulating glutathione synthesis.
Terrance J. Kavanagh, Univ. of Washington
Signal transduction pathways in the mechanisms of hepatotoxicity.
Neil Kaplowitz, Univ. of Southern California, Keck Sch. of Med.
Drug-induced enteropathy - Mechanistic insights from gene knockout models.
Urs A. Boelsterli, Univ. of Connecticut Sch. of Pharm.
Toxicology Division Business Meeting
San Diego Convention Center, Room 5A
5:30 pm - 6:30 pm
Toxicology Division/Drug Metabolism Division Joint Mixer
Marriott Hotel, Balboa Room
7:00 pm - 9:00 pm
WEDNESDAY MORNING
Protein-protein interaction (PPI) interfaces as therapeutic targets: promises and challenges
San Diego Convention Center, Room 3
9:30 am – 12:00 pm
Sponsored by the Divisions for Molecular Pharmacology; and Drug Discovery, Development & Regulatory Affairs; Toxicology
Chairs: Haian Fu, Emory Univ.
Introduction
Haian Fu, Emory Univ.
Targeting PPI interfaces in drug discovery: Key attributes of successful compounds.
David C. Fry, Hoffmann-La Roche, Inc.
Fragment-based drug discovery approach for challenging targets: PPI.
Michelle Arkin, UCSF
Computational scaffold design approach for the discovery of PPI inhibitors.
Shaomeng Wang, Univ. of Michigan
Targeting PPIs to interrogate survival signaling network in cancer.
Haian Fu, Emory Univ.
NADPH-CYP450 oxidoreductase: Roles in physiology, pharmacology, and toxicology
San Diego Convention Center, Room 4
9:30 am – 12:00 pm
Sponsored by the Divisions for Drug Metabolism; Toxicology; and Drug Discovery, Development & Regulatory Affairs; Toxicology
Chairs: Todd D. Porter, Univ. of Kentucky Col. of Pharm. and David S. Riddick, Univ. of Toronto
Introduction.
David S. Riddick, Univ. of Toronto
Engineered mouse models harboring null or hypomorphic alleles for NADPH-cytochrome P450 oxidoreductase.
Xinxin Ding, New York State Department of Health
Mouse models for deciphering the roles of NADPH-cytochrome P450 oxidoreductase and cytochrome b5 in physiology, drug metabolism and cancer.
C. Roland Wolf, Univ. of Dundee, Ninewlls Hosp. and Med. Sch., UK
Replication of the hepatic lipidosis seen in hepatic POR-null mice in a hepatoma cell culture model: A role for FXR?
Todd D. Porter, Univ. of Kentucky Col. of Pharm.
Clinical, structural and functional implications of mutations and polymorphisms in human NADPH-cytochrome P450 oxidoreductase.
Amit V. Pandey, Univ. of Bern, Switzerland
WEDNESDAY AFTERNOON
Steroid signaling via G protein-coupled receptors
San Diego Convention Center, Room 4
3:00 pm – 5:30 pm
Sponsored by the Divisions for Molecular Pharmacology; Integrative Systems, Translational & Clinical Pharmacology; Neuropharmacology; Toxicology; and Cardiovascular Pharmacology
Chairs: Eric E. Prossnitz, Univ. of New Mexico
What have selective ligands told us about GPER function?
Eric E. Prossnitz, Univ. of New Mexico
G protein-coupled estrogen receptor-1, GPER-1: its mechanism of desensitization and role in cancer.
Edward Filardo, Brown Univ. Sch. of Med.
Actions of GPER on the vasculature.
Matthias Barton, Univ. of Zurich
GPER: a GPCR mediator of estrogen actions in the brain.
Diane Lebesgue, Albert Einstein Col. of Med.
ASPET Closing Reception
Marriott Hotel, Poolside
6:00 pm - 8:00 pm